1. |
Cho JH, Ryoo NK, Cho KH, et al. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2016, 169: 79-88. DOI: 10.1016/j.ajo.2016.06.014.
|
2. |
陶勇, 侯婧, 黎晓新. 254例息肉样脉络膜血管病变的临床特征分析[J]. 中华眼底病杂志, 2012, 28(5): 441-444. DOI: 10.3760/cma.j.issn.1005-1015.2012.05.003.Tao Y, Hou J, Li XX. Chnical characteristics of 254 cases of polypoidal chomidal vasculopathy[J]. Chin J Oeul Fundus Dis, 2012, 28(5): 441-444. DOI: 10.3760/cma.j.issn.1005-1015.2012.05.003.
|
3. |
Cackett P, Wong D, Yeo I. A classification system for polypoidal choroidal vasculopathy[J]. Retina, 2009, 29(2): 187-191. DOI: 10.1097/IAE.0b013e318188c839.
|
4. |
de Silva SR, Bindra MS. Early treatment of acute submacular haemorrhage secondary to wet amd using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent[J]. Eye (Lond), 2016, 30(7): 952-957. DOI: 10.1038/eye.2016.67.
|
5. |
Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage: a series of 47 consecutive cases[J]. Arch Ophthalmol, 1995, 113(1): 62-69. DOI: 10.1001/archopht.1995.01100010064022.
|
6. |
Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator[J]. Am J Ophthalmol, 2015, 159(4): 683-689. DOI: 10.1016/j.ajo.2014.12.020.
|
7. |
于滨, 冉莉莉, 张晶, 等. 微创玻璃体手术联合雷珠单抗治疗息肉样脉络膜血管病变合并玻璃体出血和出血性视网膜脱离[J]. 中华实验眼科杂志, 2016, 34(8): 690-691. DOI: 10.3760/cma.j.issn.2095-0160.2016.08.004.Yu B, Ran LL, Zhang J, et al. Minimally invasive vitrectomy combined with ranibizumab in the treatment of polypoid choroidal vasculopathy with vitreous hemorrhage and hemorrhagic retinal detachment[J]. Chin J Exp Ophthalmol, 2016, 34(8): 690-691. DOI: 10.3760/cma.j.issn.2095-0160.2016.08.004.
|
8. |
Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients[J]. Am J Ophthalmol, 2007, 144(1): 15-22. DOI: 10.1016/j.ajo.2007.03.047.
|
9. |
Lincoff H, Madjarov B, Lincoff, N, et al. Pathogenesis of the vitreous cloud emanating from subretinal hemorrhage[J]. Arch Ophthalmol, 2003, 121(1): 91-96. DOI: 10.1001/archopht.121.1.91.
|
10. |
Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history[J]. Am J Ophthalmol, 2002, 133(5): 639-648. DOI: 10.1016/s0002-9394(02)01404-6.
|
11. |
Sandhu SS, Manvikar S, Steel DH. Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab[J]. Clin Ophthalmol, 2010, 21(4): 637-642. DOI: 10.2147/opth.s10060.
|
12. |
Wei Y, Zhang Z, Jiang X, et al. A surgical approach to large subretinal hemorrhage using pars plana vitrectomy and 360°retinotomy[J]. Retina, 2015, 35(8): 1631-1639. DOI: 10.1097/IAE.0000000000000501.
|
13. |
Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy[J]. Br J Ophthalmol, 2008, 92(1): 70-73. DOI: 10.1136/bjo.2007.122283.
|
14. |
Oishi A, Kojima H, Mandai M, et a1. Comparison of the effecc of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12 month LAPTOP study results[J]. Am J Ophthalmol, 2013, 156(4): 644-651. DOI: 10.1016/j.ajo.2013.05.024.
|
15. |
Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy[J]. Br J ophthalmol, 2018, 102(1): 97-101. DOI: 10.1136/bjophthalmol-2017-310448.
|
16. |
Yiu G, Mahmoud TH. Subretinal hemorrhage[J]. Dev Ophthalmol, 2014, 54: 213-222. DOI: 10.1159/000360469.
|